DOI 10.15252/emmm.201404792 |Published online 30.12.2014
EMBO Molecular Medicine(2014)emmm.201404792
BMC Medicine (2015) 13:42 DOI 10.1186/s12916-014-0263-6
Ann Indian Acad Neurol. 2015 Sep; 18(Suppl 1): S2–S5.
doi: 10.4103/0972-2327.164812
PMCID: PMC4604693
PMID: 26538844
For full publication see: http://hesperian.org/wp-content/uploads/pdf/sw_hmx/sw_lifestylemanual_Abmswai_2014.doc
Accessed October 2014.
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Carta Encíclica Laudato Si' de Santo Padre Francisco sobre el cuidado de la case común